266 related articles for article (PubMed ID: 28856597)
21. [Anti-hepatitis C Virus Strategy Targeting the Entry Steps].
Fukasawa M
Yakugaku Zasshi; 2019; 139(1):89-95. PubMed ID: 30606936
[TBL] [Abstract][Full Text] [Related]
22. Re-re-treatment of hepatitis C virus: Eight patients who relapsed twice after direct-acting-antiviral drugs.
Hartman J; Bichoupan K; Patel N; Chekuri S; Harty A; Dieterich D; Perumalswami P; Branch AD
World J Gastroenterol; 2015 Nov; 21(43):12430-8. PubMed ID: 26604650
[TBL] [Abstract][Full Text] [Related]
23. Current and future therapies for hepatitis C virus infection: from viral proteins to host targets.
Imran M; Manzoor S; Khattak NM; Khalid M; Ahmed QL; Parvaiz F; Tariq M; Ashraf J; Ashraf W; Azam S; Ashraf M
Arch Virol; 2014 May; 159(5):831-46. PubMed ID: 23979177
[TBL] [Abstract][Full Text] [Related]
24. Direct-acting and host-targeting HCV inhibitors: current and future directions.
Chatel-Chaix L; Germain MA; Götte M; Lamarre D
Curr Opin Virol; 2012 Oct; 2(5):588-98. PubMed ID: 22959589
[TBL] [Abstract][Full Text] [Related]
25. [Israeli guidelines for the treatment of chronic hepatitis C infection--2012 Israeli Association for the Study of the Liver].
Zuckerman E; Safadi R; Oren R; Shibolet O; Baruch Y; Bruck R; Lurei Y; Kaspa RT; Abu-Mouch S; Shouval D; Ben-Ari Z;
Harefuah; 2012 Dec; 151(12):709-14, 719. PubMed ID: 23330266
[TBL] [Abstract][Full Text] [Related]
26. Revolution in hepatitis C antiviral therapy.
Sadler MD; Lee SS
Br Med Bull; 2015 Mar; 113(1):31-44. PubMed ID: 25680808
[TBL] [Abstract][Full Text] [Related]
27. New hepatitis C virus (HCV) drugs and the hope for a cure: concepts in anti-HCV drug development.
Pawlotsky JM
Semin Liver Dis; 2014 Feb; 34(1):22-9. PubMed ID: 24782255
[TBL] [Abstract][Full Text] [Related]
28. Review of direct-acting antiviral agents for the treatment of chronic hepatitis C.
Shah N; Pierce T; Kowdley KV
Expert Opin Investig Drugs; 2013 Sep; 22(9):1107-21. PubMed ID: 23735127
[TBL] [Abstract][Full Text] [Related]
29. A profiling study of a newly developed HCVcc strain PR63cc's sensitivity to direct-acting antivirals.
Tao W; Gan T; Lu J; Zhong J
Antiviral Res; 2017 Mar; 139():18-24. PubMed ID: 28025084
[TBL] [Abstract][Full Text] [Related]
30. New HCV therapies on the horizon.
Vermehren J; Sarrazin C
Clin Microbiol Infect; 2011 Feb; 17(2):122-34. PubMed ID: 21087349
[TBL] [Abstract][Full Text] [Related]
31. [Hepatitis C virus: 25 years-old, the end?].
Pol S
Med Sci (Paris); 2013 Nov; 29(11):998-1003. PubMed ID: 24280503
[TBL] [Abstract][Full Text] [Related]
32. Changing the face of hepatitis C management - the design and development of sofosbuvir.
Noell BC; Besur SV; deLemos AS
Drug Des Devel Ther; 2015; 9():2367-74. PubMed ID: 25987834
[TBL] [Abstract][Full Text] [Related]
33. Telaprevir: changing the standard of care of chronic hepatitis C.
Rajani AK; Ravindra BK; Dkhar SA
J Postgrad Med; 2013; 59(1):42-7. PubMed ID: 23525057
[TBL] [Abstract][Full Text] [Related]
34. Treatment of chronic hepatitis C: current and future.
Pawlotsky JM
Curr Top Microbiol Immunol; 2013; 369():321-42. PubMed ID: 23463207
[TBL] [Abstract][Full Text] [Related]
35. Simeprevir: a macrocyclic HCV protease inhibitor.
Talwani R; Heil EL; Gilliam BL; Temesgen Z
Drugs Today (Barc); 2013 Dec; 49(12):769-79. PubMed ID: 24524095
[TBL] [Abstract][Full Text] [Related]
36. [RESISTANCE OF HCV TO NEW DIRECT ACTING ANTIVIRALS].
Gozlan Y; Mendelson E; Ben-Ari Z; Mor O
Harefuah; 2015 Nov; 154(11):684-7, 743. PubMed ID: 26821497
[TBL] [Abstract][Full Text] [Related]
37. Boceprevir and telaprevir in the management of hepatitis C virus-infected patients.
Butt AA; Kanwal F
Clin Infect Dis; 2012 Jan; 54(1):96-104. PubMed ID: 22156853
[TBL] [Abstract][Full Text] [Related]
38. Resistance Mechanisms in Hepatitis C Virus: implications for Direct-Acting Antiviral Use.
Bagaglio S; Uberti-Foppa C; Morsica G
Drugs; 2017 Jul; 77(10):1043-1055. PubMed ID: 28497432
[TBL] [Abstract][Full Text] [Related]
39. Novel therapeutic approaches for hepatitis C.
Au JS; Pockros PJ
Clin Pharmacol Ther; 2014 Jan; 95(1):78-88. PubMed ID: 24126682
[TBL] [Abstract][Full Text] [Related]
40. [Treatment of hepatitis C: current status and perspectives].
Pol S; Corouge M
Rev Prat; 2014 May; 64(5):605-12. PubMed ID: 24923038
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]